AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34961645
Drug: Conventional surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional surgical treatment without CANS
Trial: 32445247
Drug: Intralesional injections
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injections (ILIs) of triamcinolone acetonide (TA) combined with extracorporeal shock wave therapy (ESWT)
Trial: 32445247
Drug: Intralesional injections
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injections (ILIs) of triamcinolone acetonide (TA) alone
Trial: 32272914
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate (300 mg magnesium citrate daily)
Trial: 32272914
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule (daily)
Trial: 34151502
Drug: SciMoCa (secondary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SciMoCa (secondary Monte Carlo dose calculation)
Trial: 32666905
Drug: Electronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic treatment register used in the DeWorm3 Project for mass drug administration.
Trial: 35042751
Drug: Efpeglenatide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide (4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks)
Trial: 32001530
Drug: Intensive vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive vincristine dosing
Trial: 33940113
Drug: EvoCit (heparin-grafted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EvoCit (heparin-grafted dialyzer with citrate-enriched dialysate)
Trial: 33940113
Drug: EvoHep (heparin-grafted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EvoHep (heparin-grafted dialyzer with systemic heparin)
Trial: 35149238
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of hyperoxygenated fatty acids (HOFA) solution
Trial: 35149238
Drug: Saline physiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline physiological solution (non-HOFA)
Trial: 32077392
Drug: Olive/Soyabean lipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive/Soyabean lipid emulsion (O/S) at a dose of 0.8 g/kg per day for 7 days
Trial: 32077392
Drug: 100% Fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% Fish oil (FO) at a dose of 0.4 g/kg per day for 7 days
Trial: 38048133
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme (ACE) inhibitor
Trial: 33449924
Drug: Annual school-based
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual school-based preventive chemotherapy with praziquantel (40 mg/kg) over four years
Trial: 33449924
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment only in the first two years, followed by two years without treatment
Trial: 33449924
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment in years 1 and 3 without treatment in-between
Trial: 32414398
Drug: Ivermectin 3-monthly
RxNorm normalized name: ivermectin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 3-monthly (150 µg/kg or 800 µg/kg)
Trial: 32414398
Drug: Ivermectin annually
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin annually (150 µg/kg or 800 µg/kg)
Trial: 35930126
Drug: Galcanezumab (GMB)
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Galcanezumab (GMB) 120 mg with 240 mg loading dose
Trial: 33953828
Drug: IL-37 in
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-37 in the highest quartile (>405.3 pg/ml)
Trial: 33486528
Drug: Higher time-averaged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher time-averaged on-treatment systolic blood pressure (median: <138.3 vs. ≥138.3 mmHg)
Trial: 35847998
Drug: 2-weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-weekly docetaxel 50 mg/m2
Trial: 35847998
Drug: 3-weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-weekly docetaxel 75 mg/m2
Trial: 34121334
Drug: Petrolatum applied
RxNorm normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petrolatum applied twice daily for 8 weeks
Trial: 33345910
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg aspirin daily (Low-Risk Aspirin trial)
Trial: 33345910
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg aspirin daily (High-Risk Aspirin trial)
Trial: 33345910
Drug: Placebo (Low-Risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Low-Risk Aspirin trial)
Trial: 33345910
Drug: Placebo (High-Risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (High-Risk Aspirin trial)
Trial: 32661104
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care service (intervention group)
Trial: 35365457
Drug: Ultrasound-guided stellate
RxNorm normalized name: Mastocarpus stellatus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided stellate ganglion block (SGB) with 7 mL 0.5% ropivacaine
Trial: 35079071
Drug: TM+V (vibration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TM+V (vibration applied with 5.2±0.5 g-forces, 102.2±2.6 Hertz for 3 min)
Trial: 35767699
Drug: High-glucose mixed-nutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-glucose mixed-nutrient meal (1.1 g glucose/kg body wt)
Trial: 35428992
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg daily for 3 days
Trial: 35428992
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg thrice daily for 5 days
Trial: 35428992
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg thrice daily for 3 days
Trial: 35428992
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg thrice daily for 5 days
Trial: 35428992
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg thrice daily for 5 days
Trial: 35428992
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg thrice daily for 3 days
Trial: 36134834
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (suboptimal responders)
Trial: 36134834
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (suboptimal responders with LDL < 55 mg/dL)
Trial: 33460320
Drug: Isradipine 5-mg
RxNorm normalized name: isradipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 5-mg twice daily
Trial: 36385453
Drug: Emulsified isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emulsified isoflurane (30 mg/kg, 12% emulsified isoflurane)
Trial: 36385453
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg, 0.8% propofol)
Trial: 34708996
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2 through 90)
Trial: 34708996
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg on day 1 followed by 75 mg once daily on days 2 through 90)
Trial: 32451660
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation 25 mg/8 h for two consecutive cycles before induction of ovulation
Trial: 35319845
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with moxibustion on the affected side for 30 min once daily for 4 weeks.
Trial: 35319845
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at Zusanli(ST36), Neixiyan(EX‐LE4), Heding(EX‐LE2) and Xuanzhong(GB39) for 30 min once daily for 4 weeks.
Trial: 32231295
Drug: JNJ-67953964 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-67953964 (10 mg)
Trial: 32638239
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser treatment (LLLT)
Trial: 33052759
Drug: 3 years
RxNorm normalized name: NanoVM 1-3 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 years of sorafenib (400 mg twice per day orally, amended to 400 mg daily)
Trial: 34362410
Drug: multidisciplinary transition
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multidisciplinary transition of care program and medications’ data transfer between inpatient and outpatient caregivers
Trial: 35843080
Drug: alectinib 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alectinib 300 mg
Trial: 35843080
Drug: crizotinib 250
RxNorm normalized name: crizotinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crizotinib 250 mg
Trial: 34089596
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (three 3-week cycles of CAPOX, four 2-week cycles of FOLFOX or FOLFORI) followed by neoadjuvant chemoradiotherapy and surgery
Trial: 34089596
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery
Trial: 32268000
Drug: RO7020531 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7020531 (150 mg, multiple ascending doses every other day)
Trial: 32268000
Drug: RO7020531 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7020531 (various doses from 40 mg to 170 mg)
Trial: 32268000
Drug: RO7020531 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7020531 (100 mg or above)
Trial: 35617911
Drug: Not receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not receiving disability benefits, lower anxiety and/or depression scores, shorter duration, younger age at DS onset, employment, fewer symptoms, higher educational qualification, stronger belief in the diagnosis and in CBT as a 'logical' treatment
Trial: 32703316
Drug: medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medication plus DIT
Trial: 32703316
Drug: medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medication plus active control psychotherapy
Trial: 34703180
Drug: Oral simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral simvastatin (40 mg, daily) for 10 days
Trial: 32926010
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg orally three times/week for 12 weeks)
Trial: 33657293
Drug: Targeted 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted 20% human albumin solution for up to 14 days or until discharge; median total infusion of 200 g (IQR, 140 to 280) per patient.
Trial: 33657293
Drug: Standard care;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care; median total infusion of 20 g (IQR, 0 to 120) per patient.
Trial: 34389257
Drug: Pharmacist-administered HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-administered HPV vaccine series completion
Trial: 34389257
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group completing the HPV vaccine series at their FQHC
Trial: 36127081
Drug: Ecological Momentary
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ecological Momentary Intervention 'SmartSafe' in addition to treatment as usual (TAU)
Trial: 36127081
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) with Ecological Momentary Assessment (EMA) monitoring
Trial: 34841676
Drug: Tele-exercise classes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-exercise classes delivered via Zoom, 60-min weekly sessions by a trained exercise therapist for 3-6 months post-surgery.
Trial: 32379102
Drug: 5% monolaurin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% monolaurin vaginal gel
Trial: 32379102
Drug: Vehicle placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle placebo gel
Trial: 35661029
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (Control group)
Trial: 32332635
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment measures
Trial: 615988346
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (100 mg/mL)
Trial: 32448796
Drug: Computerised decision-support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerised decision-support tool to assist with antidepressant choices
Trial: 33075789
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol (100 mg in 100 mL normal saline over 10 min)
Trial: 33075789
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol (1 g in 100 mL normal saline over 10 min)
Trial: 35409815
Drug: Maintain daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintain daily habits
Trial: 35486088
Drug: Misoprostol tablets
RxNorm normalized name: Misoprostol Tablets
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol tablets (test product)
Trial: 35486088
Drug: Cytotec (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotec (200 μg) (reference product)
Trial: 34596484
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg OD
Trial: 34596484
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg OD
Trial: 34596484
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg OD
Trial: 39236736
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg infliximab
Trial: 36110857
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) during primary HIV infection (PHI)
Trial: 34375514
Drug: L. edodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. edodes bars (shiitake bars)
Trial: 32949011
Drug: L. sakei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. sakei proBio65 live cells (1 × 10^10 cells/day for 12 weeks)
Trial: 32949011
Drug: L. sakei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. sakei proBio65 dead cells (1 × 10^10 cells/day for 12 weeks)
Trial: 32949011
Drug: L. sakei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. sakei proBio65 live cells
Trial: 32949011
Drug: L. sakei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. sakei proBio65 dead cells
Trial: 35961661
Drug: Procedural rotation
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Procedural rotation (emergency medicine, obstetrics and gynecology)
Trial: 33071178
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (metformin alone or in combination with rosiglitazone or intensive lifestyle intervention)
Trial: 33421652
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of slow-motion and real-time video demonstration
Trial: 35982587
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (8 sessions)
Trial: 36129997
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine U-100
Trial: 32896014
Drug: Patient-centred self-administered
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centred self-administered acupressure intervention
Trial: 34453640
Drug: irinotecan‐alone (irinotecan;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan‐alone (irinotecan; 150 mg/m2, day 1, q14 days)
Trial: 34453640
Drug: paclitaxel‐alone (paclitaxel;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel‐alone (paclitaxel; 80 mg/m2, days 1, 8, 15, q28 days)
Trial: 34453640
Drug: S‐1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐1 plus irinotecan (irinotecan; 80 mg/m2, days 1, 15, S‐1; 80 mg/m2, days 1-21, q35 days)
Trial: 34453640
Drug: S‐1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐1 plus paclitaxel (paclitaxel; 50 mg/m2, day 1, 8, S‐1; 80 mg/m2, days 1-14, q21 days)
Trial: 35257740
Drug: Nebulized poractant
RxNorm normalized name: PORACTANT ALFA
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized poractant alfa 200 mg/kg
Trial: 35257740
Drug: Nebulized poractant
RxNorm normalized name: PORACTANT ALFA
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized poractant alfa 400 mg/kg
Trial: 36345917
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of photobiomodulation therapy (PBMT) and pulsed electromagnetic field therapy (PEMF)
Trial: 36345917
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PBMT and PEMF
Trial: 35351779
Drug: Medication review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication review with shared decision-making (SDM)
Trial: 36100282
Drug: Adjuvant external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant external beam radiotherapy±brachytherapy ± concomitant chemotherapy
Trial: 36100282
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment after radical surgery
Trial: 32319175
Drug: 10% topical
RxNorm normalized name: BP 10% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% topical sucralfate ointment
Trial: 33919799
Drug: Dental implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental implant coverage limited to one tooth per individual
Trial: 33919799
Drug: Dental implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental implant coverage for front teeth
Trial: 35538630
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil supplements (2000mg/day)
Trial: 33988236
Drug: Oral ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ferric maltol 30 mg twice daily
Trial: 35273052
Drug: MAMS platform
RxNorm normalized name: mAMSA
DrugBank: Amsacrine (DB00276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAMS platform trials evaluating medications
Trial: 35273052
Drug: MAMS platform
RxNorm normalized name: mAMSA
DrugBank: Amsacrine (DB00276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAMS platform trials with repurposed medications as comparison arms
Trial: 34281405
Drug: Self-Empowered UL
RxNorm normalized name: sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-Empowered UL Repetitive Engagement (SURE): individualized, UL self-exercise and use outside therapy for 6 hours/week for 4 weeks
Trial: 32423365
Drug: CHW-administered screening
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHW-administered screening questions
Trial: 32423365
Drug: GP-administered screening
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP-administered screening questions
Trial: 32423365
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of questions concerning fever, pain, and discolored drainage
Trial: 34128426
Drug: β-glucan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-glucan (6 g/day)
Trial: 34128426
Drug: inulin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inulin (6 g/day)